| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
22,187 |
20,367 |
$2.01M |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
10,632 |
10,363 |
$940K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
5,485 |
5,085 |
$450K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
2,617 |
2,546 |
$254K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
4,309 |
4,083 |
$122K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
6,029 |
5,767 |
$64K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
1,147 |
1,010 |
$58K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
1,189 |
1,147 |
$56K |
| 99000 |
|
9,947 |
9,564 |
$49K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
9,876 |
9,559 |
$47K |
| 97169 |
|
1,582 |
1,527 |
$23K |
| 99384 |
|
376 |
370 |
$14K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
1,611 |
1,548 |
$13K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
181 |
177 |
$8K |
| 87634 |
|
380 |
199 |
$8K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
151 |
144 |
$7K |
| 99215 |
Prolong outpt/office vis |
73 |
66 |
$6K |
| 87420 |
|
928 |
890 |
$6K |
| 69210 |
|
118 |
116 |
$5K |
| 99205 |
Prolong outpt/office vis |
49 |
46 |
$5K |
| 94070 |
|
42 |
40 |
$2K |
| 99383 |
|
47 |
47 |
$2K |
| A7006 |
Administration set, with small volume filtered pneumatic nebulizer |
476 |
461 |
$2K |
| 81003 |
|
918 |
881 |
$771.13 |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
12 |
12 |
$600.00 |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
73 |
63 |
$315.27 |
| 71046 |
Radiologic examination, chest; 2 views |
42 |
41 |
$229.68 |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
155 |
151 |
$162.15 |
| H0033 |
Oral medication administration, direct observation |
1,482 |
1,431 |
$40.00 |
| J7644 |
Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram |
119 |
106 |
$19.14 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
352 |
317 |
$4.18 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
90 |
82 |
$4.15 |
| 94664 |
|
39 |
32 |
$0.00 |
| S0119 |
Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) |
355 |
338 |
$0.00 |
| J7510 |
Prednisolone oral, per 5 mg |
45 |
41 |
$0.00 |
| 87807 |
|
147 |
146 |
$0.00 |
| 94761 |
|
21 |
18 |
$0.00 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
42 |
35 |
$0.00 |
| 94760 |
|
41 |
35 |
$0.00 |